Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05686876

FAPI-PET/CT in Psoriatic Arthritis

Conditions: Psoriatic Arthritis

Sex: All
Ages: 18 Years – 90 Years
Phase: EARLY_PHASE1
Enrollment: 20
Sponsor: Peking Union Medical College Hospital

Location: China

Summary

68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation, such as IgG4-related disease. Therefore, this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for disease activity assessment and follow-up of psoriatic arthritis than 18F-NAF PET/CT.

Eligibility Criteria

Inclusion Criteria:fulfilled the 2006 Classification Criteria for Psoriatic Arthritis (CASPAR)18F-NAF PET/CT within two weekssigned written consent.Exclusion Criteria:pregnancybreast feedingknown allergy against FAPIany medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05686876). StuddyBuddy aggregates publicly available trial information.